Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets hard-to-treat cancers with KRAS mutation

NCT ID NCT06128551

Disease control Sponsor: Revolution Medicines, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung, colorectal, or pancreatic cancer that has not responded to standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 534 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age * Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy 1. Phase 1b Dose Escalation: solid tumors, previously treated 2. Phase 1b Dose Expansion and Phase 2: i. NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors. * ECOG performance status 0 or 1 * Adequate organ function Exclusion Criteria: * Primary central nervous system (CNS) tumors * Active brain metastases * Known impairment of GI function that would alter the absorption * Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

appendiceal neoplasm bronchial neoplasm colonic neoplasm colorectal cancer colorectal neoplasm digestive system neoplasm endometrium neoplasm Esophageal Neoplasms gastric neoplasm intestinal cancer lung disorder lung neoplasm neoplasm Neoplasm Metastasis Neoplasms by Site non-small cell lung carcinoma ovarian cancer pancreatic ductal adenocarcinoma pancreatic neoplasm rectal neoplasm respiratory system disorder respiratory tract neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Non-small cell lung cancer (NSCLC) Pancreatic ductal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    51 sites in 7 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AUSL Romagna - S.M. delle Croci Hospital

    RECRUITING

    Ravenna, 48121, Italy

  • Allegheny Health Network

    RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

  • CHU Nantes

    RECRUITING

    Nantes, 44093, France

  • Cancer Institute of Montpellier

    RECRUITING

    Montpellier, 34298, France

  • Centre Leon Berard

    RECRUITING

    Lyon, 69373, France

  • Centro Di Riferimento Oncologico

    RECRUITING

    Aviano, 33081, Italy

  • City of Hope

    WITHDRAWN

    Duarte, California, 91010, United States

  • Columbia University

    RECRUITING

    New York, New York, 10032, United States

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle Marche

    RECRUITING

    Ancona, 60126, Italy

  • Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

  • Fundacion MD Anderson Cancer Center

    RECRUITING

    Madrid, 28033, Spain

  • Henry Ford Cancer

    WITHDRAWN

    Detroit, Michigan, 48202, United States

  • Hospital Louise Pradel

    RECRUITING

    Bron, 69500, France

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Miguel Servet

    RECRUITING

    Zaragoza, 50009, Spain

  • Hospital Universitario Virgen Macarena

    RECRUITING

    Seville, 41009, Spain

  • Institut Bergonie

    RECRUITING

    Bordeaux, 33000, France

  • Institut Catala d'Oncologia Hospital

    RECRUITING

    Barcelona, 08908, Spain

  • Institute Romagnolo per lo Studio Tumori

    RECRUITING

    Meldola, 47014, Italy

  • Institute of Cancer of Strasbourg

    WITHDRAWN

    Strasbourg, 67033, France

  • Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"

    RECRUITING

    Naples, 80131, Italy

  • Klinikum Esslingen GmbH

    RECRUITING

    Esslingen am Neckar, 73730, Germany

  • Klinkum Nurnberg Paracelsus Medical Unviersity

    RECRUITING

    Nuremberg, 90419, Germany

  • Krankenhaus Bethanien Moers

    RECRUITING

    Moers, 47441, Germany

  • La Fe University and Polytechnic Hospital

    RECRUITING

    Valencia, 46026, Spain

  • MD Anderson

    RECRUITING

    Houston, Texas, 77030, United States

  • Mary Crowley Cancer Research

    COMPLETED

    Dallas, Texas, 75230, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Moffitt Cancer Center and Research Institute

    RECRUITING

    Tampa, Florida, 33612, United States

  • NEXT Dallas

    RECRUITING

    Irving, Texas, 75039, United States

  • NEXT Oncology - Quirónsalud Madrid University Hospital

    RECRUITING

    Madrid, 28223, Spain

  • NEXT Oncology San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • NEXT Oncology Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • NYU Langone Health

    RECRUITING

    New York, New York, 10032, United States

  • Netherlands Cancer Institute Antoni van Leeuwenhoek

    RECRUITING

    Amsterdam, 1066CX, Netherlands

  • Niguarda Cancer Center

    RECRUITING

    Milan, 20162, Italy

  • Oscar Lambret Center of Lillle

    RECRUITING

    Lille, 59000, France

  • Pan American Center for Oncology Trials

    RECRUITING

    San Juan, 00935, Puerto Rico

  • START Barcelona - Hospital HM Nou Delfos

    RECRUITING

    Barcelona, 08023, Spain

  • START Madrid

    RECRUITING

    Madrid, 28040, Spain

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • START Texas

    RECRUITING

    San Antonio, Texas, 78229, United States

  • San Luigi Hospital

    RECRUITING

    Orbassano, 10043, Italy

  • Sarah Cannon Research Institue

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Stanford Cancer Institute

    RECRUITING

    Stanford, California, 94305, United States

  • UC Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

  • UC IRVINE Health

    RECRUITING

    Orange, California, 92868, United States

  • University Clinic of Navarra

    RECRUITING

    Madrid, 28027, Spain

  • University Clinic of Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • University of Colorado Cancer Center

    RECRUITING

    Aurora, Colorado, 80045, United States

  • University of Oklahoma

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • Universitäts Klinikum Köln

    RECRUITING

    Cologne, 80937, Germany

  • West Cancer Institute

    RECRUITING

    Angers, 49055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.